These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 25490866

  • 1. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.
    Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1063-70. PubMed ID: 25490866
    [Abstract] [Full Text] [Related]

  • 2. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
    Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C.
    Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD, BADBIR Study Group.
    JAMA Dermatol; 2018 May 01; 154(5):581-588. PubMed ID: 29590279
    [Abstract] [Full Text] [Related]

  • 4. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and 18fluorodeoxyglucose (FDG) positron emission tomography (PET).
    Kim SJ, Park MY, Pak K, Han J, Kim GW, Kim HS, Ko HC, Kim MB, Kim BS.
    J Dermatolog Treat; 2018 Dec 01; 29(8):761-768. PubMed ID: 29658378
    [Abstract] [Full Text] [Related]

  • 5. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C, Creighton-Smith M, Sorensen EP, Dumont N, Gottlieb AB.
    J Drugs Dermatol; 2015 Aug 01; 14(8):881-6. PubMed ID: 26267734
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE.
    Value Health; 2018 Jan 01; 21(1):1-8. PubMed ID: 29304933
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K, Burden AD, Eaton JN, Hawkins NS.
    Br J Dermatol; 2012 Jan 01; 166(1):179-88. PubMed ID: 21910698
    [Abstract] [Full Text] [Related]

  • 8. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    Carrera CG, Dapavo P, Malagoli P, Naldi L, Arancio L, Gaiani F, Egan CG, Di Mercurio M, Cattaneo A.
    J Dermatolog Treat; 2018 Aug 01; 29(5):481-486. PubMed ID: 29058948
    [Abstract] [Full Text] [Related]

  • 9. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
    Ross C, Marshman G, Grillo M, Stanford T.
    Australas J Dermatol; 2016 May 01; 57(2):137-40. PubMed ID: 25754697
    [Abstract] [Full Text] [Related]

  • 10. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
    Zhang M, Goren A, Lee S, DiBonaventura MD, Olson WH.
    J Dermatolog Treat; 2016 Aug 01; 27(4):339-45. PubMed ID: 26558924
    [Abstract] [Full Text] [Related]

  • 11. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C, Beauchet A, Burztejn AC, Severino-Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj-Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour JP, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse AC, Kupfer-Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles-Tsimaratos N, Mery-Brossard L, Pallure V, Lons-Danic D, Bouilly-Auvray D, Beylot-Barry M, Puzenat E, Aubin F, Mahé E, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie.
    J Eur Acad Dermatol Venereol; 2019 Oct 01; 33(10):1984-1992. PubMed ID: 30883928
    [Abstract] [Full Text] [Related]

  • 12. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.
    Griffiths CEM, Fava M, Miller AH, Russell J, Ball SG, Xu W, Acharya N, Rapaport MH.
    Psychother Psychosom; 2017 Oct 01; 86(5):260-267. PubMed ID: 28903122
    [Abstract] [Full Text] [Related]

  • 13. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.
    J Am Acad Dermatol; 2018 Jul 01; 79(1):135-144.e7. PubMed ID: 29438757
    [Abstract] [Full Text] [Related]

  • 14. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
    Malatestinic W, Nordstrom B, Wu JJ, Goldblum O, Solotkin K, Lin CY, Kistler K, Fraeman K, Johnston J, Hawley LL, Sicignano N, Araujo A.
    J Manag Care Spec Pharm; 2017 Mar 01; 23(3):370-381. PubMed ID: 28230450
    [Abstract] [Full Text] [Related]

  • 15. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
    Sorensen EP, Fanucci KA, Saraiya A, Volf E, Au SC, Argobi Y, Mansfield R, Gottlieb AB.
    J Drugs Dermatol; 2015 Aug 01; 14(8):893-8. PubMed ID: 26267736
    [Abstract] [Full Text] [Related]

  • 16. Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study.
    Svedbom A, Wennerström C, Hjelm F, Tjärnlund A, Ståhle M.
    J Dermatolog Treat; 2024 Dec 01; 35(1):2398170. PubMed ID: 39229963
    [Abstract] [Full Text] [Related]

  • 17. Biologic drug survival in Israeli psoriasis patients.
    Shalom G, Cohen AD, Ziv M, Eran CB, Feldhamer I, Freud T, Berman E, Oren S, Hodak E, Pavlovsky L.
    J Am Acad Dermatol; 2017 Apr 01; 76(4):662-669.e1. PubMed ID: 28038888
    [Abstract] [Full Text] [Related]

  • 18. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
    van den Reek JMPA, Coenen MJH, van de L'Isle Arias M, Zweegers J, Rodijk-Olthuis D, Schalkwijk J, Vermeulen SH, Joosten I, van de Kerkhof PCM, Seyger MMB, Zeeuwen PLJM, de Jong EMGJ.
    Br J Dermatol; 2017 May 01; 176(5):1288-1296. PubMed ID: 27564082
    [Abstract] [Full Text] [Related]

  • 19. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study.
    Marinas JE, Kim WB, Shahbaz A, Qiang JK, Greaves S, Yeung J.
    Australas J Dermatol; 2018 Feb 01; 59(1):e11-e14. PubMed ID: 27858976
    [Abstract] [Full Text] [Related]

  • 20. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.
    Onsun N, Akaslan TÇ, Sallahoglu K, Gülcan AS, Bulut H, Yabacı A.
    J Dermatolog Treat; 2022 May 01; 33(3):1727-1732. PubMed ID: 33704001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.